Repeated magnetic resonance imaging in esophageal cancer for adaptive radiation treatment planning during chemoradiotherapy.

Repeated magnetic resonance imaging in esophageal cancer for adaptive radiation treatment planning during chemoradiotherapy. - REACT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46841

Enrollment

Registered

2015-07-22

Start date

2015-12-30

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer oesophageal carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Histologically confirmed squamous-cell carcinoma, adenocarcinoma or large-cell undifferentiated carcinoma of the esophagus or esophagogastric junction (i.e. tumors involving both cardia and esophagus on endoscopy) - For nCRT: potentially resectable tumor (cT1b-4b N0-3 M0) and undergoing preoperative chemoradiation according to CROSS-regimen - For dCRT: unresectable tumor (T4bNxM0) or medically unfit patient for surgery due to comorbidities based on multidisciplinary consensus, undergoing definitive chemoradiation - Age>18 years - Signed informed consent

Exclusion criteria

Exclusion criteria: - Patients who meet exclusion criteria for MRI following the protocol of the department of Radiology of the UMC Utrecht. -Patients who meet exclusion criteria for Gadovist gadolinium (Glomerular Filtration Rate (GFR) of

Design outcomes

Primary

Measure	Time frame
Observational study to analyse esophageal tumor regression and tumor movement during nCRT in order to develop adaptive radiotherapy planning strategies using intratreatment delineations of MR images to improve target coverage and critical organ sparing.	—

Secondary

Measure	Time frame
Only applicable to patients with resectable esophageal cancer: Besides the primary endpoint anatomical and functional MR images will be used to further assess and evaluate the optimal time of scanning during nCRT to predict pathological response to treatment with pathology of the resected specimen as reference standard. Furthermore, the value of 'dynamic contrast-enhanced MRI' for early response assessment during nCRT will be assessed.	—

Measure

Time frame

Only applicable to patients with resectable esophageal cancer: Besides the primary endpoint anatomical and functional MR images will be used to further assess and evaluate the optimal time of scanning during nCRT to predict pathological response to treatment with pathology of the resected specimen as reference standard. Furthermore, the value of 'dynamic contrast-enhanced MRI' for early response assessment during nCRT will be assessed.

—

Countries

Netherlands

Outcome results